• ME/CFS and long COVID; negative outcomes for ALS drug; donanemab

  • Apr 18 2024
  • Length: 5 mins
  • Podcast

ME/CFS and long COVID; negative outcomes for ALS drug; donanemab cover art

ME/CFS and long COVID; negative outcomes for ALS drug; donanemab

Listen for free

View show details

  • Summary

  • Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that explores an association between myalgic encephalomyelitis/chronic fatigue and long COVID; negative phase 3 findings on AMX0035 for ALS, and the pending approval of donanemab for Alzheimer’s disease.
    Show More Show Less
Physical Illness & Disease Hygiene & Healthy Living
Show More Show Less

What listeners say about ME/CFS and long COVID; negative outcomes for ALS drug; donanemab

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com.au reviews

Amazon Reviews
No Reviews are Available
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.